Esophageal cancer: Risk factors, genetic association, and treatment
- PMID: 27986415
- DOI: 10.1016/j.asjsur.2016.10.005
Esophageal cancer: Risk factors, genetic association, and treatment
Abstract
The poor prognosis and rising incidence of esophageal cancer highlight the need for improved detection and prediction methods that are essential prior to treatment. Esophageal cancer is one of the most fatal malignancies worldwide, with a dramatic increase in incidence in the Western world occurring over the past few decades. Despite improvements in the management and treatment of esophageal cancer patients, the general outcome remains very poor for overall 5-year survival rates (∼10%) and 5-year postesophagectomy survival rates (∼15-40%). Esophageal cancer is often diagnosed during its advanced stages, the main reason being the lack of early clinical symptoms. In an attempt to improve the outcome of patients after surgery, such patients are often treated with neoadjuvent concurrent chemoradiotherapy (CCRT) in order to decrease tumor size. However, CCRT may enhance toxicity levels and possibly cause a delay in surgery for patients who respond poorly to CCRT. Thus, precise biomarkers that could predict or identify patients who may or may not respond well to CCRT can assist physicians in choosing the appropriate therapy for patients. Identifying susceptible gene and biomarkers can help in predicting the treatment response of patients while improving their survival rates.
Keywords: esophageal cancer; genetic factors; risk factors.
Copyright © 2016. Published by Elsevier Taiwan.
Comment in
-
Esophageal cancer-related multiple primary cancers (MPCs).Asian J Surg. 2018 Sep;41(5):519-521. doi: 10.1016/j.asjsur.2018.06.002. Epub 2018 Aug 3. Asian J Surg. 2018. PMID: 30078502 No abstract available.
Similar articles
-
Recent developments in esophageal adenocarcinoma.CA Cancer J Clin. 2013 Jul-Aug;63(4):232-48. doi: 10.3322/caac.21185. CA Cancer J Clin. 2013. PMID: 23818335 Review.
-
High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.Ann Surg Oncol. 2014 Jul;21(7):2361-8. doi: 10.1245/s10434-014-3611-z. Epub 2014 Mar 13. Ann Surg Oncol. 2014. PMID: 24623035
-
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.Cancer. 2006 Sep 1;107(5):967-74. doi: 10.1002/cncr.22077. Cancer. 2006. PMID: 16874819
-
Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation.Dis Esophagus. 2011 Nov;24(8):590-5. doi: 10.1111/j.1442-2050.2011.01195.x. Epub 2011 May 3. Dis Esophagus. 2011. PMID: 21539673 Clinical Trial.
-
Genomics of Esophageal Cancer and Biomarkers for Early Detection.Adv Exp Med Biol. 2016;908:237-63. doi: 10.1007/978-3-319-41388-4_12. Adv Exp Med Biol. 2016. PMID: 27573775 Review.
Cited by
-
Time-trend of the incidence and mortality of esophageal cancer from 2010 to 2018 and its statistics in 2018 in Henan, China.Ann Transl Med. 2022 Aug;10(16):899. doi: 10.21037/atm-22-4027. Ann Transl Med. 2022. PMID: 36111000 Free PMC article.
-
The Use of Trimodality Treatment in Patients With Locally Advanced Oesophageal Squamous Cell Carcinoma: An Experience From a Large Cancer Centre in Pakistan.Cureus. 2023 Oct 27;15(10):e47835. doi: 10.7759/cureus.47835. eCollection 2023 Oct. Cureus. 2023. PMID: 38021746 Free PMC article.
-
Exploring the Mechanism of Realgar against Esophageal Cancer Based on Ferroptosis Induced by ROS-ASK1-p38 MAPK Signaling Pathway.Evid Based Complement Alternat Med. 2022 Sep 12;2022:3698772. doi: 10.1155/2022/3698772. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36133791 Free PMC article.
-
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.Cell Rep Med. 2024 Aug 20;5(8):101664. doi: 10.1016/j.xcrm.2024.101664. Epub 2024 Jul 31. Cell Rep Med. 2024. PMID: 39089259 Free PMC article.
-
Pathologic Features of Esophageal and Gastric Malignancies.Cancer Treat Res. 2024;192:19-48. doi: 10.1007/978-3-031-61238-1_2. Cancer Treat Res. 2024. PMID: 39212914 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous